Quotient (QTNT) Prices 17.647M Upsized Common Offering at $4.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pre-Open Movers 09/10: (VRTU) (RH) (NAV) Higher; (STSA) (PRPL) (NKLA) Lower (more...)
September 10, 2020 9:32 AM EDTToday's Pre-Open Movers
Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) 80% LOWER; announced topline results from its Phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal) powder as an acute treatment for migraine. Although topline data showed numerical differences in favor of STS101 3.9 mg and 5.2 mg versus placebo on the pre-specified co-primary endpoints of freedom from pain and freedom from most bothersome symptom (from among photophobia, phonophobia and nausea) at two hours post-administration, these differences did not achieve statistical significance for either dosage strength. Both dosage strengths of STS101 did, however,... More
After-Hours Movers 09/09: (RMTI) (RH) (SLQT) Higher; (PRPL) (GME) (BIGC) Lower (more...)
September 9, 2020 5:57 PM EDTToday's After-Hours Movers
Rockwell Medical, Inc. (Nasdaq: RMTI) 32.5% HIGHER; entered into an exclusive license agreement with Jeil Pharmaceutical Co., Ltd. (Jeil), for the rights to commercialize Triferic (ferric pyrophosphate citrate) in South Korea.
Purple Innovation, Inc. (NASDAQ: PRPL) 14.7% LOWER; announced the launch of an underwritten secondary public offering of 11,826,087 shares of its Class A common stock to be sold by InnoHold, LLC (the "Selling Stockholder").
Quotient (QTNT) Announces Proposed $60M Common Share Offering
September 9, 2020 4:17 PM EDTQuotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of $60 million of its ordinary shares. All of the ordinary shares to be sold in the offering will be offered by the Company. In... More
